Kyverna Therapeutics Shares Are Trading Higher After the Company Announced KYV-101 Received FDA IND Clearance for the Treatment of Patients With Treatment-refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
Kyverna Therapeutics股票正在高价交易,该公司宣布KYV-101已获得FDA IND许可,用于治疗KYSA-8第2阶段试验中的治疗耐药性强的Stiff-Person综合症患者